Marengo to Present Initial Results from Invikafusp Alfa and TRODELVY® Combination Study, STARt-002, at the 2025 San Antonio Breast Cancer Symposium
- Safety profile of Invikafusp alfa + TRODELVY® is consistent with the known profiles of each agent
- Invikafusp alfa demonstrates selective expansion of Vβ6/10 T cells when combined with TRODELVY® in previously treated metastatic breast cancer
- Early anti-tumor activity observed in majority of patients, recommended dose selected for phase 2 expansion cohorts currently enrolling at select North American cancer centers
Excerpt from the Press Release:
CAMBRIDGE, Mass., Dec. 12, 2025 /PRNewswire/ — Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapy for oncology and inflammation & immunology (I&I), today unveiled initial clinical results from its ongoing STARt-002 phase 1b/2 trial during a late breaking presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS) taking place December 9-12.
Early findings from the combination study of Invikafusp alfa (Invika) and TRODELVY® (sacituzumab govitecan-hziy; SG) suggest that this novel regimen, which leverages two key modalities (immunotherapy and ADCs), is well tolerated and biologically active across all dose levels evaluated. The safety profile of the combination was consistent with the known profiles of each agent.
“The early safety and pharmacodynamic data from STARt-002 are highly encouraging,” said Steven Isakoff, M.D., Ph.D., Director of Breast Cancer Clinical Research at the Massachusetts General Hospital Cancer Center. “The combination of Invika with TRODELVY® is scientifically compelling — pairing targeted T cell activation with ADC-mediated tumor killing. Seeing consistent Vβ6/10 expansion alongside early tumor responses reinforces the potential of this regimen to meaningfully benefit patients with metastatic breast cancer, and I look forward to the results from the ongoing phase 2 cohorts.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?